Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability.

Hamblett KJ, Le T, Rock BM, Rock DA, Siu S, Huard JN, Conner KP, Milburn RR, O'Neill JW, Tometsko ME, Fanslow WC.

Mol Pharm. 2016 Jul 5;13(7):2387-96. doi: 10.1021/acs.molpharmaceut.6b00153. Epub 2016 Jun 13.

PMID:
27248573
2.

SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm.

Hamblett KJ, Jacob AP, Gurgel JL, Tometsko ME, Rock BM, Patel SK, Milburn RR, Siu S, Ragan SP, Rock DA, Borths CJ, O'Neill JW, Chang WS, Weidner MF, Bio MM, Quon KC, Fanslow WC.

Cancer Res. 2015 Dec 15;75(24):5329-40. doi: 10.1158/0008-5472.CAN-15-1610. Epub 2015 Dec 2.

3.

Intracellular Catabolism of an Antibody Drug Conjugate with a Noncleavable Linker.

Rock BM, Tometsko ME, Patel SK, Hamblett KJ, Fanslow WC, Rock DA.

Drug Metab Dispos. 2015 Sep;43(9):1341-4. doi: 10.1124/dmd.115.064253. Epub 2015 Jun 22.

PMID:
26101225
4.

AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma.

Hamblett KJ, Kozlosky CJ, Siu S, Chang WS, Liu H, Foltz IN, Trueblood ES, Meininger D, Arora T, Twomey B, Vonderfecht SL, Chen Q, Hill JS, Fanslow WC.

Mol Cancer Ther. 2015 Jul;14(7):1614-24. doi: 10.1158/1535-7163.MCT-14-1078. Epub 2015 Apr 30.

5.

Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment.

McDonagh CF, Turcott E, Westendorf L, Webster JB, Alley SC, Kim K, Andreyka J, Stone I, Hamblett KJ, Francisco JA, Carter P.

Protein Eng Des Sel. 2006 Jul;19(7):299-307. Epub 2006 Apr 27.

PMID:
16644914
6.

Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides.

Sun MM, Beam KS, Cerveny CG, Hamblett KJ, Blackmore RS, Torgov MY, Handley FG, Ihle NC, Senter PD, Alley SC.

Bioconjug Chem. 2005 Sep-Oct;16(5):1282-90.

7.

Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics.

Cerveny CG, Law CL, McCormick RS, Lenox JS, Hamblett KJ, Westendorf LE, Yamane AK, Petroziello JM, Francisco JA, Wahl AF.

Leukemia. 2005 Sep;19(9):1648-55.

PMID:
16049514
8.

Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma.

Hamblett KJ, Press OW, Meyer DL, Hamlin DK, Axworthy D, Wilbur DS, Stayton PS.

Bioconjug Chem. 2005 Jan-Feb;16(1):131-8.

PMID:
15656584
9.

Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.

Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF, Meyer DL, Francisco JA.

Clin Cancer Res. 2004 Oct 15;10(20):7063-70.

10.

A streptavidin-biotin binding system that minimizes blocking by endogenous biotin.

Hamblett KJ, Kegley BB, Hamlin DK, Chyan MK, Hyre DE, Press OW, Wilbur DS, Stayton PS.

Bioconjug Chem. 2002 May-Jun;13(3):588-98.

PMID:
12009950

Supplemental Content

Loading ...
Support Center